BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Viriom Selects ChemDiv, Inc. to Develop HIV Program


10/19/2009 12:05:08 PM

SAN DIEGO, CA--(Marketwire - October 19, 2009) - ChemDiv, Inc. (ChemDiv) of San Diego has proudly announced that its wholly owned subsidiary Chemical Diversity Research Institute (CDRI ) of Moscow, Russia, has been chosen by Viriom Ltd. ( Viriom) of Moscow, Russia as a service partner in developing innovative HIV compounds. The program includes pre-clinical and clinical studies, which are expected to begin in 2010.

Viriom has recently signed the license agreement with Roche. Under the terms of this agreement Roche granted Viriom development and commercialization rights for potential novel HIV/AIDS medicine in Russia, Ukraine, Belarus and Kazakhstan. Subject to performance of the program Viriom will also receive license fees, development milestones and royalties on worldwide sales.

Vadim Bichko, Vice President Virology at ChemDiv, Inc., said: "We are excited about this new collaboration with Viriom and Roche. These novel HIV inhibitors have shown excellent antiviral properties in vitro, good bioavailability, PK and safety profiles, as well as a high genetic barrier to resistance. Based on pre-clinical studies to date, these molecules have the potential to become best in class HIV drugs."

About VIRIOM

VIRIOM Ltd. is an innovative company that was established in 2009 to develop targeted medicines for HIV/AIDS. Basis is the Center of High Technologies ChemRar to which VIRIOM is affiliated. VIRIOM is planning to conduct research and clinical trials in Russia using the experience and knowledge of Russian scientists. Chemical Diversity Research Institute, Prudentas Ltd. and Drug Technologies Ltd.of ChemRar Hi Tech Center (ChemRar) as well as Moscow City Center for prevention and treatment of HIV/AIDS were selected as partners in this program.

About ChemDiv, Inc.

ChemDiv collaborates with pharmaceutical and biotech partners by enabling them to accelerate their R&D programs to higher value clinical inflection points. ChemDiv provides integrated drug discovery and early clinical development, extracting value from potential therapeutic candidates via rapid, streamlined outcomes and effective use of capital.

ChemDiv is the only vertically and horizontally integrated discovery and development CRO headquartered in San Diego, CA, with: unique access to the Eastern European emerging pharma market; rational drug design and medicinal chemistry in a broad range of therapeutic areas of target classes; world's largest small molecule inventory; working with 20 top pharma and 100 top biotechs in all major markets.

With its successful 20 year business record in life sciences and over 500 research associates equivalent employed globally, ChemDiv has successfully prosecuted fully integrated programs from target to Proof of Concept (POC) and market registration.

About Chemical Diversity Research Institute.

CDRI is a contract research organization focused on pre-clinical and clinical R&D. CDRI sees its mission in enabling discovery and development of innovative therapies for unmet needs utilizing the highest expertise and innovation potential of Russian scientists with integrated external R&D solutions of Discovery outSource™ platforms. Discovery outSource™ platform solutions cover the complete range of disciplines from identification of a biological target (protein expression, assay development etc.); to clinical drug candidates (ADME/DMPK, toxicity and safety studies, in vivo animal models, drug formulation etc.); to drug development candidate (Phase I to Phase IV).

About ChemRar Hi Tech Center

ChemRar High-Tech Center is a unique pharma and biotechnology conglomerate built in Moscow, Russian Federation by highly innovative life science R&D organizations, discovering, developing and commercializing novel drugs for partners in Russia and worldwide. It sees its mission in bringing novel therapies for unmet needs in treating CNS, oncology, cardiovascular, metabolic and infection disease through using novel post genomic technology platforms.


Contact for ChemDiv:
Ronald Demuth
SVP & General Manager
6605 Nancy Ridge Drive
San Diego, CA 92121
Phone: (858) 794-4860
Fax: (858)794-4931
Email: Email Contact

Contact for Viriom:
Irina Tyrnova
COO
Rabochaya 2a/1, Khimki
Moscow, Russia 141400
Phone: +7-495-995-4944
Email: Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES